Vitamin E for NAFLD and MASH: The PIVENS Trial and Why Hepatologists Still Prescribe 800 IU

Non-alcoholic fatty liver disease, recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), affects roughly a quarter of adults globally. A subset progress to steatohepatitis (MASH) with fibrosis. Drug development has been slow, and the AASLD guidelines list very few interventions with histological benefit. Vitamin E is one of them, on the strength of the PIVENS trial and a small number of replication studies.

PIVENS: the trial that put vitamin E on the AASLD list

The PIVENS trial, published in NEJM in 2010, randomized 247 non-diabetic adults with biopsy-proven NASH to 800 IU per day of natural-source d-alpha-tocopherol, 30 mg of pioglitazone, or placebo for 96 weeks. The vitamin E arm met the prespecified primary endpoint of improvement in NAFLD activity score, with histological resolution of steatohepatitis in 36 percent versus 21 percent on placebo [1]. Pioglitazone showed similar metabolic but weaker histological benefit. Liver enzymes fell in both treatment arms. No mortality benefit was studied — the trial was powered for histology.

TONIC: the same effect in adolescents

The TONIC trial randomized 173 children and adolescents with NAFLD to 800 IU of vitamin E, metformin, or placebo for 96 weeks. Vitamin E produced a higher rate of histological resolution of NASH than placebo (58 percent vs 28 percent), with the largest effect in those with definite NASH at baseline [2]. The pediatric finding has not been replicated at scale, but TONIC remains the basis for cautious vitamin E use in pediatric NASH at specialist centers.

The diabetic NASH question

PIVENS deliberately excluded patients with diabetes, so the original AASLD guidance limited vitamin E to non-diabetic adults with biopsy-proven NASH. A 2019 single-center trial by Bril and colleagues in patients with type 2 diabetes and biopsy-confirmed NASH found that 400 IU twice daily of vitamin E plus pioglitazone improved histology more than pioglitazone alone, suggesting the effect generalizes to diabetics with combination therapy [3]. The 2023 AASLD practice guidance now considers vitamin E in selected diabetic patients on a case-by-case basis.

The hemorrhagic stroke and prostate cancer caveats

The major concerns about long-term high-dose alpha-tocopherol come from non-NASH trials. The SELECT trial of 400 IU vitamin E for prostate cancer prevention found a 17 percent relative increase in prostate cancer over 7 years follow-up [4]. The Physicians' Health Study II reported a small increase in hemorrhagic stroke with 400 IU every other day [5]. A 2005 meta-analysis by Miller and colleagues suggested all-cause mortality rises modestly above 400 IU per day, although later analyses with more trials have not consistently replicated this signal [6]. These risks must be weighed against the histological benefit in NASH.

Form, dose, and what to ask for

The trials used d-alpha-tocopherol, not dl-alpha-tocopherol or mixed tocopherols. The 800 IU dose corresponds to roughly 536 mg of d-alpha-tocopherol. Patients should not self-prescribe long-term high-dose vitamin E without hepatology supervision. INR may rise modestly in those on warfarin. The use case is biopsy-proven MASH in non-diabetic adults or pediatric patients in research-grade hepatology settings — not generic "fatty liver" picked up on incidental ultrasound.